Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Australian Red Cross Blood Service, Ringwood, VIC

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the supply and manufacturing of therapeutic goods within the country, ensuring that they meet safety, quality, and efficacy standards. This Act empowers the Therapeutic Goods Administration (TGA) to issue licences for the manufacture of therapeutic goods and to revoke such licences where necessary, ensuring that the standards set forth in the Act are maintained. This particular Gazette, C2014G00230, published on 30 January 2014 by Harry Rothenfluh, a delegate of the Secretary of the Department of Health, informs of the revocation of a manufacturing licence for therapeutic goods. In this instance, the licence held by the Australian Red Cross Blood Service – An Operating Division of The Australian Red Cross Society – Licence Number MI-17082005-LI-000787-1 for their Blood Donor Centre in Ringwood, Victoria, has been revoked at the request of the manufacturer. This revocation aligns with the policy objective of the Therapeutic Goods Act to maintain high standards in the manufacture of therapeutic goods, ensuring public health and safety.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and persons engaged in the manufacture, supply, and importation of therapeutic goods within Australia. This legislation governs the quality, safety, efficacy, and proper use of therapeutic goods, ensuring that they meet the necessary standards before they are made available to consumers. The Act applies to a wide range of therapeutic goods, including medicines, medical devices, blood and blood components, and therapeutic goods that involve human cells or tissues. The Act's jurisdiction extends across the Commonwealth of Australia, impacting both national and international entities involved in the manufacture and distribution of these goods. The revocation of a manufacturer’s licence, as seen in the case of the Australian Red Cross Blood Service, is a specific application of the Act's provisions. This revocation may be at the request of the manufacturer or imposed by the Secretary, depending on compliance and operational standards. While the Act provides a comprehensive framework for regulating therapeutic goods, certain exclusions and exemptions may apply, often detailed in subordinate instruments or specific regulations that further refine the application of the Act.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") provides a framework for the regulation of therapeutic goods in Australia, including their manufacture, distribution, and quality. Section 41(1)(d) of the Act allows the Secretary to revoke a manufacturer's licence under certain conditions. In this instance, the Secretary has revoked the Licence held by The Australian Red Cross Blood Service – An Operating Division of The Australian Red Cross Society, Licence No. MI-17082005-LI-000787-1, which pertained to the Blood Donor Centre Ringwood located at Unit 1, 32-38 Charter Street, Ringwood, VIC, 3134. This revocation occurred at the request of the manufacturer themselves. The Act imposes various obligations on parties involved in the manufacture of therapeutic goods. Manufacturers must comply with stringent standards to ensure the safety and efficacy of the products they produce. This includes adhering to Good Manufacturing Practice (GMP) standards, maintaining thorough records, and ensuring that their facilities and processes are suitable for the production of therapeutic goods. The revocation of a licence, as seen here, serves as a significant enforcement tool, highlighting the importance of compliance and the consequences of non-compliance. Failure to meet the requirements of the Act can result in severe consequences, both civil and criminal. Offences under the Act can lead to penalties that vary depending on the nature and severity of the breach. For example, if a manufacturer fails to comply with the GMP standards, they may face financial penalties up to a maximum of $1,215,000 for a corporation and $243,000 for an individual, as stipulated in the Act. Furthermore, serious breaches may result in criminal charges, which can lead to imprisonment for up to five years for individuals and higher fines for corporations. The revocation of a licence, as documented in the gazette, is one such consequence that underscores the seriousness with which the Therapeutic Goods Administration treats non-compliance.